135 related articles for article (PubMed ID: 34653249)
1. JAK2 wild-type erythrocytosis associated with sodium-glucose cotransporter 2 inhibitor therapy.
Gangat N; Szuber N; Alkhateeb H; Al-Kali A; Pardanani A; Tefferi A
Blood; 2021 Dec; 138(26):2886-2889. PubMed ID: 34653249
[No Abstract] [Full Text] [Related]
2. Effect of sodium-glucose cotransporter-2 inhibitors on pulmonary arterial wedge pressure.
Karakasis P; Patoulias D; Giannakoulas G; Rosenkranz S; Fragakis N
Eur J Intern Med; 2024 Jun; 124():147-149. PubMed ID: 38458878
[No Abstract] [Full Text] [Related]
3. Ketonuria/ketonemia associated with the use of sodium-glucose cotransporter 2 (SGLT-2) inhibitors in type 2 diabetes: A report of three cases from New Delhi, India.
Ghosh A; Gupta R; Misra A
J Diabetes; 2016 Sep; 8(5):738-9. PubMed ID: 27085074
[No Abstract] [Full Text] [Related]
4. Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population.
Wittbrodt ET; Eudicone JM; Bell KF; Enhoffer DM; Latham K; Green JB
Am J Manag Care; 2018 Apr; 24(8 Suppl):S138-S145. PubMed ID: 29693360
[TBL] [Abstract][Full Text] [Related]
5. Comparative Genitourinary Safety of In-class Sodium-Glucose Cotransporter-2 Inhibitors among Patients with Heart Failure with Preserved Ejection Fraction: A Cohort Study.
Riaz M; Guo J; Smith SM; Dietrich EA; Winchester DE; Park H
Am J Cardiovasc Drugs; 2024 May; 24(3):455-464. PubMed ID: 38691312
[TBL] [Abstract][Full Text] [Related]
6. Class effects of SGLT2 inhibitors on cardiorenal outcomes.
Kluger AY; Tecson KM; Lee AY; Lerma EV; Rangaswami J; Lepor NE; Cobble ME; McCullough PA
Cardiovasc Diabetol; 2019 Aug; 18(1):99. PubMed ID: 31382965
[TBL] [Abstract][Full Text] [Related]
7. The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury.
Chu C; Lu YP; Yin L; Hocher B
Kidney Blood Press Res; 2019; 44(2):149-157. PubMed ID: 30939483
[TBL] [Abstract][Full Text] [Related]
8. A Review of Sodium Glucose Co-transporter 2 Inhibitors Canagliflozin, Dapagliflozin and Empagliflozin.
Syed SH; Gosavi S; Shami W; Bustamante M; Farah Z; Teleb M; Abbas A; Said S; Mukherjee D
Cardiovasc Hematol Agents Med Chem; 2015; 13(2):105-12. PubMed ID: 26549321
[TBL] [Abstract][Full Text] [Related]
9. Effects of sodium glucose co-transporter 2 inhibitors on the kidney.
de Albuquerque Rocha N; Neeland IJ; McCullough PA; Toto RD; McGuire DK
Diab Vasc Dis Res; 2018 Sep; 15(5):375-386. PubMed ID: 29963920
[TBL] [Abstract][Full Text] [Related]
10. Cardiorenal Outcomes in the CANVAS, DECLARE-TIMI 58, and EMPA-REG OUTCOME Trials: A Systematic Review.
Kluger AY; Tecson KM; Barbin CM; Lee AY; Lerma EV; Rosol ZP; Rangaswami J; Lepor NE; Cobble ME; McCullough PA
Rev Cardiovasc Med; 2018 Jun; 19(2):41-49. PubMed ID: 31032602
[TBL] [Abstract][Full Text] [Related]
11. Sodium-glucose cotransporter 2 inhibitors and diabetic ketoacidosis.
Bloomgarden ZT
J Diabetes; 2016 Mar; 8(2):175-6. PubMed ID: 26611882
[No Abstract] [Full Text] [Related]
12. Use of sodium-glucose cotransporter-2 inhibitors and urinary tract infections in type 2 diabetes patients: a systematic review.
Figueiredo IR; Rose SCP; Freire NB; Patrocínio MS; Pierdoná N; Bittencourt RJ
Rev Assoc Med Bras (1992); 2019 Feb; 65(2):246-252. PubMed ID: 30892451
[TBL] [Abstract][Full Text] [Related]
13. Generalizability of Cardiovascular Safety Trials on SGLT2 Inhibitors to the Real World: Implications for Clinical Practice.
Nicolucci A; Candido R; Cucinotta D; Graziano G; Rocca A; Rossi MC; Tuccinardi F; Manicardi V
Adv Ther; 2019 Oct; 36(10):2895-2909. PubMed ID: 31410779
[TBL] [Abstract][Full Text] [Related]
14. Dapagliflozin-Associated Diabetic Ketoacidosis.
Chakinala RC; Chang AP; Solanki S; Haq KF; Cho R
Am J Ther; 2018; 25(6):e765-e766. PubMed ID: 29672334
[No Abstract] [Full Text] [Related]
15. Empagliflozin (Jardiance) for heart failure with reduced ejection fraction.
Med Lett Drugs Ther; 2021 Nov; 63(1636):171-172. PubMed ID: 35085205
[No Abstract] [Full Text] [Related]
16. Impact of SGLT Inhibitors on Multiple Organ Defects in Diabetes.
Asrih M; Gariani K
Curr Diabetes Rev; 2020; 16(5):411-418. PubMed ID: 31702506
[TBL] [Abstract][Full Text] [Related]
17. SGLT2 inhibitors and metformin: Dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes.
Donnan K; Segar L
Eur J Pharmacol; 2019 Mar; 846():23-29. PubMed ID: 30639796
[TBL] [Abstract][Full Text] [Related]
18. Sodium-glucose cotransporter 2 inhibitors for treating diabetes mellitus.
Goldberg N; Fralick M
CMAJ; 2017 May; 189(20):E724. PubMed ID: 28536128
[No Abstract] [Full Text] [Related]
19. Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME.
Verma S; Mazer CD; Al-Omran M; Inzucchi SE; Fitchett D; Hehnke U; George JT; Zinman B
Circulation; 2018 Jan; 137(4):405-407. PubMed ID: 29133602
[No Abstract] [Full Text] [Related]
20. SGLT2-inhibitors in type-2 diabetes: The remaining questions!
Rajput R; Ved J
Diabetes Metab Syndr; 2017 Nov; 11 Suppl 1():S433-S438. PubMed ID: 28395977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
